As previously reported, H.C. Wainwright upgraded Adlai Nortye (ANL) to Buy from Neutral with a $16 price target after the company announced it dosed the first patient in it Phase 1 study evaluating AN9025 for the treatment of advanced, metastatic solid tumors with RAS mutations. The firm, which is “encouraged” by Adlai’s parallel clinical track for China and the U.S. and the recent partnership with ASK Pharm, is upgrading shares based on the “differentiated pipeline reset and market opportunities.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANL:
- Adlai Nortye upgraded to Buy from Neutral at H.C. Wainwright
- Adlai Nortye Doses First Patient in Global Phase 1 Trial of Pan-RAS Inhibitor AN9025
- Adlai Nortye Secures $140 Million PIPE Financing to Support Oncology Pipeline
- Adlai Nortye prices 64.6M shares at $2.17 in private placement
- Adlai Nortye Ltd (ADR) trading resumes